Bio News
Oncology candidate REC-1245 demonstrates safety in early clinical trial<br>18 months from target discovery to IND; company aims to obtain efficacy data by year-end
Recursion Pharmaceuticals increased the efficiency of drug candidate discovery by up to 15-fold through its AI platform, while the oncology candidate REC-1245 demonstrated safety in an early clinical trial without dose-limiting toxicity. REC-1245 is an RBM39 protein degrader that has not previously been drugged, and the process from target discovery to approval of the investigational new drug (IND) application was completed in 18 months. The company is currently enrolling patients in the high-dose cohort and aims to obtain its first efficacy data by the end of this year.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
